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A case of sarcoptic mange aﬀecting almost all the animals of a dairy goat herd is described. This pruritic skin disease led
progressively to high mortality and dramatic drop of milk yield. The lesions of the aﬀected goats were typical of a chronic and
generalized-diﬀuse sarcoptic mange. Diagnosis was conﬁrmed by skin scrapings and histopathology in which many mites were
demonstrated. All surviving goats were treated with injectable moxidectin solution 1% (CYDECTIN-Fort Dodge) at the dose of
0.2mg/kg, applied every 15 days for four times, subcutaneously. Although pruritus had decreased soon after the ﬁrst treatment,
a satisfactory healing of cutaneous lesions was witnessed 6 weeks after the beginning of moxidectin trial. Parasitological cure was
achieved in all aﬀected animals by the end of the trial. In the four monthly followups, no evidence of sarcoptic mange could be
found.
1.Introduction
Sarcoptic mange is a highly contagious and pruritic acariosis
of the skin aﬀecting more than 100 domestic and wild
mammalian species, including humans [1–3]. The causative
mite, Sarcoptes scabiei, inﬂicts damage to the skin mainly by
forming tunnels within the upper epidermal layers [4]. The
mite is transmitted by direct contact or with fomites [5]. The
disease has been reported to aﬀect mainly the traditional
goat herds, with the newly purchased animals known to
serve as the main source of the contamination [2, 6, 7].
Dairy goat enterprises are an important part of livestock
production in Greece [8]. Although sarcoptic mange is
a common ectoparasitic disease in this country, aﬀecting
almost all domestic animal species and especially pigs,
goats, sheep, and dogs [9–11], there have been no adequate
epidemiological studies to address the problem among small
ruminant ﬂocks or herds.
Intense pruritus, manifested over the face, pinnae, neck,
limbs, or over the body and associated with the presence
of papules, crusts, excoriations, and hypotrichosis-alopecia,
on an erythematous or hyperpigmented, licheniﬁed, thick,
and folded skin make up the typical clinical picture of
sarcoptic mange as it appears in the goat. The aﬀected
animals usually die at the ﬁnal stage of the disease, preceded
by anorexia, emaciation or cachexia, lethargy, and lagging
behind [2, 12–14].
The application of systemic acaricidal treatment in dairy
goat herds is questionable because of the residue problem of
themilk[15]andtheinconsistencyoftherapeuticalresultsso
far obtained [6, 13, 16]. The macrocyclic lactone moxidectin
h a sb e e np r o v e nt ob eas a f ea n de ﬀective endoparasiticide2 Veterinary Medicine International
in goats [17–19] and a valuable acaricide for the sarcoptic
mange of the other domestic animal species [20], though has
neverbeentestedforthispurposeinthecaprinecounterpart,
at least to our knowledge. The aim of this paper was to eval-
uate its eﬃcacy in chronic, generalized, and debilitating sar-
coptic mange aﬀecting a traditional goat herd and resulting
in high morbidity and mortality rates as well as a dramatic
milk yield along with substantial losses, carcasses, and hides.
2.CaseReport
2.1. Historical Data. The goat herd, located on a hilly area of
northern Greece, was comprised of 700 goats belonging to a
native breed (Capra prisca) and organized in a semiextensive
system. In a 3-month period beginning from the end of the
winter, the farmer noticed a quickly spreading and intensely
pruritic dermatopathy that eventually aﬀected almost every
goat in the herd and eventually resulted in the death of
400 out of 700 animals (57%). According to the farmer, the
problem had emerged two months after the introduction of
a few goats purchased from another enterprise. The farmer
had been advised to treat the aﬀected animals with a single
subcutaneous injection of ivermectin (0.3mg/kg) but of
no avail, as only a temporary and mild improvement was
observed soon, followed by a relapse of clinical signs.
2.2. Clinical and Laboratory Findings. Three adult female
goats, where admitted to the Farm Animal Clinic (Veterinary
Faculty, Aristotle University of Thessaloniki, Greece), with
a generalized and diﬀuse skin disease that was highly
pruritic characterized by alopecia-hypotrichosis, erythema,
hyperpigmentation, excoriations, thick crusts, skin fold-
ing, and licheniﬁcation (Figure 1(a)) .T h e s ea n i m a l sw e r e
also emaciated (Figure 1(b))a n da n o r e c t i cw i t hn oa c t u a l
milk yield. They all died after a couple of days without
treatment or any other type of clinical intervention and
were soon necropsied thereafter. The only macroscopic
ﬁndings were emaciation and bacterial bronchopneumonia
with Pasteurella multocida as its cause. All the goats were
tested negative for Mycoplasma spp., paratuberculosis, and
lentiviral infection. Similar clinical signs, the severity of
which varied, were also observed in all the other aﬀected
goats during a visit to the goat farm.
Microscopic examination of multiple skin scrapings,
obtained from new skin lesions (papules) of all, a total of 8,
goats revealed the presence of several Sarcoptes mites as well
as their eggs and fecal pellets. Eight mm punch skin biopsies,
obtained from the skin lesions of the neck and thoracic
wall of each of the ﬁrst three scabietic goats, were processed
routinely and stained with hematoxylineosin. The ensuing
histopathological examination disclosed a severe orthok-
eratotic and laminated hyperkeratosis, epidermal acantho-
sis, and spongiosis as well as superﬁcial perivascular to
interstitial dermatitis with a strong eosinophilic component
within the cellular inﬁltrate; several mites were also found
embedded within the stratum corneum (Figure 2).
2.3. Treatment. A l ls u r v i v i n gg o a t s( 3 0 0t o t a l l y )w e r et r e a t e d
with moxidectin after having secured a written consent from
the farmer. Study protocol and technical details were also
approved by the Institutional Animal Care in the prefecture
ofThessaloniki, Greece.Aninjectablemoxidectin solutionof
1%(CYDECTIN-FortDodge)wasappliedsubcutaneouslyat
the dose of 0.2mg/kg every 15 days and for a total of four
treatments. The milk yield was much reduced and discarded
as toxic because of the moxidectin residues. At the same
time, the goat premises were thoroughly cleaned and sprayed
with an acaricidal aqueous solution containing 2000ppm
amitraz (TAK-TIC-Intervet) in an eﬀort to eliminate the re-
contamination potential.
Moxidectin treatment, applied successfully to all goats of
this herd, resulted in a dramatic decrease of mortality rate
(1%), as only 3 emaciated to cachectic animals died shortly
thereafter. Although pruritus level decreased profoundly
within 15 days after the ﬁrst moxidectin injection, it took
almost 6 weeks for the cutaneous lesions to disappear and
to witness partial haircoat regrowth. Parasitological cure was
achieved at the same time for the majority of the goats, apart
from those with severe and generalized/diﬀuse skin disease
in which two more weeks were allowed, coinciding with
the end of 8-week trial with moxidectin. In all four clinical
and parasitological reexaminations, performed during the
following 3 months, no evidence of sarcoptic mange could
be demonstrated, with the appetite and body weight of the
aﬀected animals restored back to normal. Haircoat regrew
completely 5 months after the beginning of moxidectin trial,
whereas milk yield never reached the preacariosis level, at
least during the ongoing lactation period. However, it was
restored back to normal level during the next one.
3. Discussion
Sarcoptic mange is a common ectoparasitic disease in the
majority of the countries with many goat enterprises [3,
16, 21]. In this herd, the morbidity rate was much higher
c o m p a r e dt ow h a th a sb e e nr e p o r t e di ns o m eS o u t hA s i a n
countries [12]. The increased morbidity rate, noticed in
this study, could be attributed to a combination of factors
such as poor nutrition and hygiene level and overcrowding
conditions. Mortality rate was quite high (57%) and most
likely was the result of the severity, generalization, and
chronicity of the disease itself although higher rates have
been reported in various wild ruminant species [22, 23].
Prolonged anorexia due to intense pruritus led to the debility
and emaciation, or predisposed to secondary bacterial infec-
tions (e.g., bacterial bronchopneumonia), all ﬁnally leading
to the death of the aﬀected goats. Bacterial complications
have also been incriminated as the cause of death in scabietic
cattle [24].
Apart from the animal losses, the farmer was worried
about the dramatic drop of milk yield also reported in
similarly aﬀected sheep [25] and cattle and attributed to
the signiﬁcant reduction of food intake secondary to intense
pruritus [24].
Sarcoptic mange in goats can be treated with parenteral
ivermectin [16] and/or lime sulfur [13], herbal [26], or
organophosphate dips [16]. However, the topical treatments,Veterinary Medicine International 3
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Figure 1: Lateral and dorsal view of a one-year-old female goat with sarcoptic mange, showing the typical skin lesions of the disease and the
emaciation of the animal.
Figure2:Skinbiopsyobtainedfromlesionalskin,inwhichahyper-
plastic superﬁcial dermatitis, along with several Sarcoptes scabiei
mites embedded within the hyperkeratotic stratum corneum, is
s h o w n( H & E5 0 x ) .
apart from resulting in toxic side eﬀects, had low eﬃcacy
rates and frequent relapses [6, 16]. In this goat herd, the
treatment with parenteral moxidectin coupled with the
application of frequent cleaning and disinfection measures
within the goat premises was found to be both eﬃcacious
and uneventful. Moxidectin alone or in combination with
other medication has been successfully used in the treatment
of sheep [10, 25], cattle [27], horses [28], dogs, and rabbits
[20, 29]a ﬀected with sarcoptic mange. In dairy farms, this
treatmentisnotadvisableduringthemilkingperiod,because
moxidectinisalipophilicmoleculeandmuchofitisexcreted
intothemilk[30].However,intheseverelyaﬀectedgoatherd
of this paper this was not a problem, as the milk production
had reached a minimal level, and the collected milk had been
discarded during the 8-week trial with moxidectin.
4. Conclusion
Sarcoptic mange is a common problem in our traditional
goat herds, leading to heavy animal losses if left untreated.
This preliminary open trial has shown that treatment with
moxidectin is eﬀective, safe, and practical also for goats,
especially when it is coupled with thorough cleaning and
disinfection of the premises with acaricidal solutions.
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